Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Ranchi"

123 News Found

Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
Drug Approval | January 02, 2025

Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA

DOVBLERON marks the 13th addition to Innovent’s commercial portfolio


JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
News | November 07, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth


RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
News | November 07, 2024

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25


Biocon reports Q2 FY25 net loss at Rs. 16 Cr
News | November 04, 2024

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore


Davaindia accelerates expansion with 1,165 operational stores
News | October 08, 2024

Davaindia accelerates expansion with 1,165 operational stores

Strategic focus on COCO-model with a nationwide reach of 501 stores


Briefs: Krsnaa Diagnostics and Anuh Pharma
News | September 27, 2024

Briefs: Krsnaa Diagnostics and Anuh Pharma

Krsnaa Diagnostics receives LoI from RINPAS for radiology services


Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
News | August 31, 2024

Thyrocare to acquire diagnostic and pathological services business of Vimta Labs

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025


Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
News | August 30, 2024

Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan

Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025


Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024
News | August 27, 2024

Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024

New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases